晚期黑色素瘤患者接受免疫治疗时联用抗血栓治疗可改善生存——基于前瞻性皮肤癌登记ADOReg的2419例患者多中心研究
基于德国前瞻性多中心皮肤癌登记ADOReg中2419例接受免疫检查点抑制剂(ICI)治疗的晚期不可切除黑色素瘤患者,按是否联用血小板聚集抑制(PAI)、抗凝(AC)或未用抗血栓药分组。结果显示联用阿司匹林或抗凝者无进展生存改善,多因素分析中DOAC或苯丙香豆素与总生存风险降低相关。作者认为抗凝和抗血小板联用药物可能具有正向预后作用,需进一步研究确认。
要点
- 联用阿司匹林者无进展生存15.1个月 vs 未用抗血栓药者6.4个月,HR 0.67(95%CI 0.5–0.88,p=0.0047)。
- 联用抗凝者无进展生存15.1个月 vs 未用抗血栓药者6.4个月,HR 0.7(95%CI 0.53–0.91,p=0.01)。
- 多因素分析中DOAC(HR 0.68,95%CI 0.49–0.92,p=0.0170)或苯丙香豆素(HR 0.44,95%CI 0.19–0.85,p=0.0301)与总生存风险降低相关。
核心结论
- 本研究提示抗凝和抗血小板联用药物对接受ICI的黑色素瘤患者具有正向预后作用,需进一步研究确认联合抗凝或血小板抑制的肿瘤相关获益。
研究设计与样本
- 研究纳入德国前瞻性多中心皮肤癌登记ADOReg中2419例接受ICI治疗的晚期不可切除黑色素瘤患者。
- 按ICI开始时是否记录使用血小板聚集抑制(PAI,n=137;阿司匹林或氯吡格雷)、抗凝(AC,n=185;直接口服抗凝药、苯丙香豆素、肝素)或ICI治疗期间任何时点未用抗血栓药(n=2097)分组。
- 研究终点为最佳总体缓解(BOR)、无进展生存(PFS)和总生存(OS)。
主要发现
- 与未记录使用抗血栓药者相比,记录使用阿司匹林者PFS为15.1 vs 6.4个月,HR 0.67(95%CI 0.5–0.88,p=0.0047)。
- 与未记录使用抗血栓药者相比,记录使用抗凝者PFS为15.1 vs 6.4个月,HR 0.7(95%CI 0.53–0.91,p=0.01)。
- 多因素分析显示接受DOAC者OS风险降低(HR 0.68,95%CI 0.49–0.92,p=0.0170),接受苯丙香豆素者OS风险降低(HR 0.44,95%CI 0.19–0.85,p=0.0301)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究确认在ICI治疗中加入抗凝或血小板抑制的肿瘤相关获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis. Preclinical studies indicate a beneficial effect, clinical data has been inconsistent. METHODS: We examined a cohort of advanced, non-resectable melanoma patients (n = 2419) derived from the German prospective multicenter skin cancer registry ADOReg, who were treated with immune checkpoint inhibitors (ICI). The patients were classified based on whether it was documented that they received platelet aggregation inhibition (PAI) (n = 137) (acetylsalicylic acid (ASA) or clopidogrel), anticoagulation (AC) (n = 185) (direct oral anticoagulation (DOAC), phenprocoumon, heparins) at the start of ICI or no antithrombotic medication (n = 2097) at any point during ICI treatment. The study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS). RESULTS: A significantly improved PFS was observed in patients documented to receive ASA (15.1 vs 6.4 months, HR 0.67, 95 % CI: 0.5 to 0.88, p = 0.0047) as well as in patients to receive AC (15.1 vs. 6.4 months, HR 0.7, 95 % CI: 0.53 to 0.91, p = 0.01) compared to patients for whom no antithrombotic medication was documented. Multivariate analysis of OS showed significant risk reduction in patients who received DOAC (HR 0.68, 95 % CI: 0.49 to 0.92, p = 0.0170) or phenprocoumon (HR: 0.44, 95 % CI: 0.19 to 0.85, p = 0.0301). CONCLUSION: Our study indicates a positive prognostic effect of anticoagulant and antiplatelet concomitant medication in melanoma patients receiving ICI. Further studies are needed to confrim the cancer-related benefit of adding anticoagulation or platelet inhibition to ICI treatment.
引用
- Kött J, Zell T, Zimmermann N, et al. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg. Eur J Cancer. 2024. PMID: 39642845. doi:10.1016/j.ejca.2024.115159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。